科研业绩
作为主持人承担各级科研项目十余项，累计科研经费超200万，包括国家自然科学基金2项🦸🏽♀️，入选上海市浦江人才计划等。以第一作者和通讯作者发表学术论文五十余篇，其中SCI论文三十余篇，多次国际会议口头发言，获中国发明专利授权两项，为多本SCI收录杂志审稿专家𓀝，参加多项全国多中心临床研究𓀛🖐🏻。作为主要参与者获教育部科学技术进步奖一等奖1项，华夏医学科技奖三等奖1项。
近五年的代表性论文：
1)Guo H#, Jin C#, Ding L, Xie J, Xu J, Wang R, Wang H, Guo C, Zhang J, Peng B, Yao X, Yuan J*, Yang B*. De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review. Chin Med J (Engl). 2024 Sep 27. doi: 10.1097/CM9.0000000000003311. (PMID: 39350461, Article, Corresponding author, IF=7.5)
2)Xie J#, Guo H#, Dong B#, Chen W#, Jin C, Xu Q, Ding L, Liu W, Dong S, Zhao T, Yu Y, Guo C, Yao X*, Peng B*, Yang B*. Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study. Eur Urol Oncol 2024 Oct;7(5):1088-1096. (PMID: 38458891, Article, Corresponding author, IF=8.3).
3)Liu W#, Kadier A#, Shen D, He Y, Dong S, Zhu K, Xu G, Zhao B, Mao S, Guo C, Yao X, Wei Q, Han D*, Yang B*. Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial. BMJ Open, 2024;14(3):e080593. (PMID: 38431292, Article, Corresponding author, IF=2.4).
4)Yang B#*, Zhao T#, Dong B#, Chen W#, Yang G, Xie J, Guo C, Wang R, Wang H, Huang L, Peng B, Xue W*, Yao X*. Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer. iScience, 2024;27(2):108931. (PMID: 38327772, Article, First author and Corresponding author, IF=4.6).
5)Xu J, Ding L, Yang B*. Re: Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with [(177)Lu]Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-resistant Prostate Cancer (TheraP): Secondary Outcomes of a Randomised, Open-label, Phase 2 Trial. Lancet Oncol 2024;25:99-107. Eur Urol Oncol, 2024. (PMID: 38378399, Letter, Corresponding author, IF=8.3).
6)Liu W, He Y, Yang B*. Re: Cathrine Alvaer Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, Henrik Gronberg, Bjornar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009. Eur Urol Focus, 2024. (PMID: 38290858 , Letter, Co-Corresponding author, IF=4.8)
7)Yang B#, Yang G#, Zhao F, Yao X, Xu L*, Zhou L*. Autologous Endothelial Progenitor Cells and Bioactive Factors Improve Bladder Regeneration. Tissue Eng Part C Methods, 2024;30(1):15-26. (PMID: 37756374, Article, First author, IF=2.7).
8)Ding L, Yang B*, Yao X*. Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108. Eur Urol, 2023.(PMID: 38000965 , Letter, Co-Corresponding author, IF=25.3)
9)Wang H#, Liu J#, Zhu X#, Yang B*, He Z*, Yao X*. AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification. Research (Wash D C), 2023;6:0252.(PMID: 37854295, Article, Co-Corresponding author, IF=8.5)
10)Wang R#, Xu Q#, Guo H#, Yang G, Zhang J, Wang H, Xu T, Guo C, Yuan J, He Y, Zhang X, Fu H, Xu G, Zhao B, Xie J, Zhao T, Huang L, Zhang J, Peng B, Yao X*, Yang B*. Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer. Cancer Res Commun, 2023;3(11):2221-2232. (PMID: 37877742, Article, Corresponding author🏸， IF=2.0)
11)Fu H, Liang S, Xu M, Guo J, Liu Q, Kang J, Zhang L, Liu Z, Ding L, Ma Y, Yang B, Yao X, Qi J, Wang H, Cai Y. An 18F-MD-PSMA (Multi-dentate PMSA Imaging Agent) PET/CT in Prostate Cancer Relapse: Results of a Retrospective Trial. Curr Radiopharm, 2023. doi: 10.2174/1874471016666230915103157.( PMID: 37724670, Article, Co-author, IF=1.5)
12)Song G, Li Y, Hou H, Wang Y, Wang X, Niu S, Tu X, Shen H, Zhou Z, Wang Y, Yan R, Xu N, Zhang G, Hao H, Zhang S, Liu B, Yang B, Wang B, Wang H, Huang H, Zhang Q, Dong B, Li Y, Bi J, Yan W, Guo H, Niu Y, Yang G, Liu M, Wei Q, Xing N. Indications, strategies, and development on prostate targeted biopsy: Report of the Panjiayuan Consensus Conference 2022. UroPrecision, 2023;1(1):3-19.
13)Wang H#, Li N#, Liu Q#, Guo J, Pan Q, Cheng B, Xu J, Dong B, Yang G, Yang B, Wang X, Gu Y, Zhang G, Lian Y, Zhang W, Zhang M, Li T, Zang Y, Tan M, Li Q, Wang X, Yu Z, Jiang J*, Huang H*, Qin J*. Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer Cell, 2023;41(7):1345-1362 e1349. (PMID: 37352863, Article, IF=48.8)
14)Xu G, Li JH, Xiang LH, Yang B, Chen YC, Sun YK, Zhao BH, Wu J*, Sun LP, Xu HX. Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy. Asian J Androl, 2023;25(3):410-415. (PMID: 36348578, Article, Co-author, IF=3.0)
15)Du X, Fei X, Wang J, Dong Y, Fan L, Yang B, Chen W, Gong Y, Xia B, Zhu H, Wu F, Wang Y, Dong L, Zhu Y, Pan J, Yao X, Dong B. Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer. Translational Oncology, 2023;34:101701. (PMID: 37247504, Article, Co-author, IF=4.5)
16)Xu T#, Guo H#, Xie J, He Y, Peng B, Che J, Yang B*,Yao X*. Sustained complete response to first-line immunochemotherapy for highly-aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture and non-mesenchymal state: a case report and literature review. Front. Oncol. 2023.doi: 10.3389/fonc.2023.1119343. (PMID: 37427135, Co-Corresponding author, IF=3.5).
17)Maskey N#, Mao S#, Yang G#, Guo Y, Kadier A, Yuan J, Xie J, Guo C, Yang B*, Yao X*. Perioperative change of circulating tumor cells in cytoreductive radical prostatectomy for oligometastatic hormone-sensitive prostate cancer: the preliminary safety evidence from long-term oncologic outcomes. Int Urol Nephrol, 2023;55(7):1709-1717. (PMID: 37160485, Article, Co-Corresponding author, IF=1.8).
18)Xu T#, Gu W#, Wang X*, Xia L, He Y, Dong F, Yang B*, Yao X*. Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature. World J Surg Oncol, 2022;20(1):226. (PMID: 35794571, Article, Co-Corresponding author, IF=2.5).
19)Dong B#, Yang B#, Chen W#, Du X#, Fan L#, Yao X*, Xue W*. Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis. Medical oncology, 2022;39(5):96. (PMID: 35599270, Article, Co-First author, IF=2.8)
20)Yang G#, Xie J#, Guo Y, Yuan J, Wang R, Guo C, Peng B, Yao X*, Yang B*. Identifying the Candidates Who Will Benefit from Extended Pelvic Lymph Node Dissection at Radical Prostatectomy among Patients with Prostate Cancer. Front. Oncol. 2022. doi: 10.3389/fonc.2021.790183. (PMID: 35155191, Article, Co-Corresponding author, IF=3.5)
21)Yang G#, Xie J#, Zhang S, Gu W, Yuan J, Wang R, Guo C, Ye L, Peng B, Yao X*, Yang B*. Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy. Front. Oncol. 2022. 11:812549. doi: 10.3389/fonc.2021.812549. (2022) (PMID: 35127528, Article, Co-Corresponding author, IF=3.5)
22)Yang B*, Yang G, Yao X. Re: Karim A. Touijer, Daniel D. Sjoberg, Nicole Benfante, et al. Limited Versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.03.006. Eur Urol Oncol. 2021. (PMID: 34535419, Letter, First author and Corresponding author, IF=8.3)
23)Dong B#, Fan L#, Yang B#, Chen W#, Li Y#, Wu K#, Zhang F#, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L, Yao X*, Xue W*. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. J Natl Compr Canc Netw, 2021:1-10. (PMID: 33990090, Article, Co-First author, IF=14.8)
